Experimental H5N1 vaccine shows promise in dairy calves and mice
Bottom line
Researchers at the University of Nebraska–Lincoln reported preclinical results for an experimental H5N1 vaccine that generated strong immune responses in mice and Holstein dairy calves, and fully protected vaccinated mice from lethal challenge with divergent H5N1 strains, including a 2024 bovine isolate from Ohio. The candidate uses a centralized consensus H5 antigen delivered in a prime-boost regimen with serotype-switched adenoviral vectors, given both intramuscularly and intranasally to try to build systemic and mucosal immunity. The findings are described in a forthcoming npj Vaccines paper and were highlighted by the university in late April. (news.unl.edu)
Why it matters: For veterinary professionals, this is an early but notable proof-of-concept at a time when H5N1 remains a cattle health, workforce health, and biosecurity concern. There are still no licensed H5N1 vaccines for cattle, and USDA’s response has centered on surveillance, including the National Milk Testing Strategy and mandatory testing tied to interstate movement of lactating dairy cattle. A vaccine that can reduce clinical disease, viral burden, and farm-to-farm spread could eventually become an important complement to testing and biosecurity, especially as H5N1 has now been confirmed in dairy herds across multiple states and continues to raise zoonotic concerns. (news.unl.edu)
What to watch: The next key step is whether these immunogenicity findings in calves translate into challenge-protection data in cattle, followed by regulatory and field-development work that would determine whether a bovine H5N1 vaccine can move toward real-world use. (nature.com)
A University of Nebraska–Lincoln team says it has developed an experimental H5N1 vaccine that protected mice against lethal disease and produced strong immune responses in dairy calves, offering an early look at what a cattle-targeted vaccination strategy could become if avian influenza remains entrenched in U.S. dairy production. The work comes as the industry continues to adapt to the unprecedented spillover of highly pathogenic H5N1 into dairy cattle first identified in March 2024. (news.unl.edu)
The candidate arrives against a fast-moving backdrop. Since the virus was first confirmed in U.S. dairy cattle, federal and state officials have expanded surveillance through mandatory interstate movement testing and USDA’s National Milk Testing Strategy. Researchers and public health officials have also been watching the cattle outbreak closely because it changed the epidemiology of H5N1 from a poultry-centered problem into a broader livestock and zoonotic issue. (aphis.usda.gov)
In the npj Vaccines paper, the Nebraska group described a “centralized consensus” H5 immunogen designed to sit near the center of the H5 phylogenetic tree, with the goal of broad cross-strain coverage. The vaccine was delivered through adenoviral vectors in a serotype-switched prime-boost approach, combining intramuscular and intranasal administration to stimulate both bloodstream and mucosal immunity. In mice, vaccinated animals were fully protected against lethal challenge with divergent H5N1 strains, including a bovine 2024 isolate. In calves, the study showed strong serum antibody, nasal IgA, and cell-mediated immune responses after vaccination. (nature.com)
Those cattle data matter because the calf arm was focused on immunogenicity, not on challenge protection. The study used eight one-week-old male Holstein dairy calves, split into two vaccinated groups, with prime vaccination on day 0 and a boost on day 28, followed by tissue collection on day 42. That makes this a promising preclinical signal, but still an early-stage one. It shows the platform can generate the kinds of immune responses researchers want to see in cattle, without yet answering how well it prevents infection, shedding, or transmission under field conditions. (nature.com)
Outside experts have been arguing that this is exactly the kind of work the dairy sector needs. Gregory Gray at the University of Texas Medical Branch wrote recently that vaccinating dairy cattle could be one of the most important steps the U.S. can take to reduce viral circulation on farms, lower spillover risk to people and other species, and protect nearby poultry operations. He also noted that dairy systems already have the recordkeeping and routine herd-health infrastructure that could make vaccine deployment practical if an effective product becomes available. (utmb.edu)
Why it matters: For veterinarians, the Nebraska study adds scientific support to the idea that H5N1 vaccination in cattle is technically feasible, and maybe strategically useful, even if commercialization is still a long way off. If future studies show that vaccination reduces disease severity, milk loss, shedding, or transmission, it could reshape herd-level H5N1 management by adding an immunization tool to today’s testing, movement controls, worker-protection measures, and farm biosecurity. That would be especially relevant in a disease event with animal health, public health, and business continuity implications. (nature.com)
There are still important practical questions. Regulators would need evidence on efficacy in cattle, duration of immunity, effects on diagnostics and surveillance, strain matching, manufacturing scale, and how vaccination might affect trade and control policy. Because USDA’s current framework is built around detection and movement oversight, any vaccine pathway would likely need to fit into that larger surveillance architecture rather than replace it. That’s an inference based on the current federal response, but it is consistent with how APHIS has structured its dairy H5N1 program so far. (aphis.usda.gov)
What to watch: Expect the next milestones to be cattle challenge studies, durability data, and any signals that developers or federal agencies are moving from promising preclinical research toward a defined regulatory path for bovine H5N1 vaccination. (nature.com)